Dequan Pharmaceuticals

Dequan Pharmaceuticals is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of novel small molecule drugs for metabolic and oncological conditions. The company's primary focus is on addressing unmet medical needs in non-alcoholic steatohepatitis (NASH) and other metabolic disorders. Its lead program, DQ-1001, is a potent and selective thyroid hormone receptor beta (THR-beta) agonist currently undergoing clinical evaluation. Dequan's research strategy emphasizes the optimization of drug-like properties to enhance therapeutic windows and patient outcomes. Founded by Dr. Dequan Zou, the company integrates advanced medicinal chemistry with efficient clinical development pathways.